Other clinical studyDecreased right heart blood volume determined by magnetic resonance imaging: evidence of central underfilling in cirrhosis☆
References (38)
- et al.
Arterial underfilling does not cause sodium retention in cirrhosis
Am J Med
(1993) - et al.
Pathogenesis of sodium retention in cirrhosis
J Hepatol
(1993) Medical treatment of ascites in cirrhosis
J Hepatol
(1993)- et al.
Reduced central blood volume in cirrhosis
Gastroenterology
(1989) - et al.
Pathogenesis of sodium retention complicating cirrhosis: is there room for diminished “effective” arterial blood volume?
Gastroenterology
(1988) - et al.
Atrial volume in cirrhosis: relationship to blood volume and plasma concentrations of atrial natriuretic factor
Gastroenterology
(1990) - et al.
Paracentesis in the management of cirrhotic ascites
J Hepatol
(1993) - et al.
Hepatopulmonary syndrome: clinical observations and lack of therapeutic response to somatostatin analogue
Chest
(1993) - et al.
Na restriction blunts expansion of plasma volume and ameliorates hyperdynamic circulation in portal hypertension
Am J Physiol
(1990) - et al.
Temporal relationship of peripheral vasodilatation, plasma volume expansion and the hyperdynamic circulatory state in portal-hypertensive rats
Hepatology
(1992)
Impaired pressor reactivity in cirrhosis: Evidence for a peripheral vascular defect
Hepatology
The relationship of plasma volume, portal hypertension, ascites, and renal sodium retention in cirrhosis: the overflow theory of ascites formation
Ann NY Acad Sci
Underfilling versus overfilling in hepatic ascites
N Engl J Med
Peripheral artery vasodilatation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis
Hepatology
Hyperdynamic state in chronic liver diseases
J Hepatol
Mechanism of sodium retention and ascites formation in cirrhosis
J Hepatol
Ascites formation in liver cirrhosis: the how and the why
Dig Dis
Liver disease and renal complications
Estimated central blood volume in cirrhosis: relationship to sympathetic nervous activity, beta-adrenergic blockade and atrial natriuretic factor
Hepatology
Cited by (83)
Retrospective analysis of liver cirrhosis influence on heart walls thickness
2015, Pathology Research and PracticeCitation Excerpt :As there are no previous references, we can only theorize that pulmonary vasodilation (being the cause of hepatopulmonary syndrome [4,20]) can lead to right ventricle adaptive atrophy. Also, decreased right ventricle preload (indicated by decrees in right ventricular end systolic and end diastolic volume [21]) could be another cause, but this matter is uncertain – other studies present contradictory data – right ventricle dilation [13,20,22], although it can be an effect of right ventricle diastolic dysfunction [20], not an effect of increased preload. In light of so few and so conflicting data, it seems obvious that further research investigating the right ventricle in LC is needed.
The effects of transjugular intrahepatic portosystemic stent shunt on systemic cardiocirculatory parameters
2014, Journal of Critical CareNew insights into cirrhotic cardiomyopathy
2013, International Journal of CardiologyIncreased B-type natriuretic peptide during liver transplantation: Relationship to invasively measured hemodynamic parameters
2012, Transplantation ProceedingsCirrhotic cardiomyopathy
2010, Journal of HepatologyCitation Excerpt :Analogously to the normal resting cardiac pressures in cirrhosis, changes in the size of the cardiac volumes are only modest. As assessed by magnetic resonance imaging, there seems to be a trend towards slightly increased left ventricular end-diastolic and left atrial volumes, probably in relation to the presence of diastolic dysfunction [64–66]. Increased atrial natriuretic peptide (ANP) in some patients with cirrhosis may reflect distension or distortion of the atria, a finding that may coexist with effective hypovolaemia [67,68].
Endogenous cannabinoids in liver disease: Many darts for a single target
2010, Gastroenterologia y Hepatologia
- ☆
Supported by the John and Birthe Meyer Foundation, the NOVO Foundation, and the Medical Research Foundation, Copenhagen, Denmark.